 NEW YORK, July 06, 2021 GLOBE NEWSWIRE -- Y-mAbs Therapeutics, Inc. Y-mAbs, NASDAQ: YMAB, a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that SciClone Pharmaceuticals Holdings Limited SciClone Pharmaceuticals has submitted the Biologics License Application BLA for DANYELZA naxitamab-gqgk for the treatment of patients with relapsedrefractory high-risk neuroblastoma to the National Medical Products Administration NMPA of China. 